Bank of America Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $93.00

PTC Therapeutics (NASDAQ:PTCT) had its price target dropped by Bank of America from $97.00 to $93.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price objective suggests a potential upside of 33.05% from the company’s previous close.

PTCT has been the topic of a number of other reports. Wells Fargo & Company set a $86.00 price objective on shares of PTC Therapeutics in a research note on Friday. Barclays raised PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $68.00 to $119.00 in a research report on Tuesday, January 27th. Wall Street Zen raised PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Finally, Jefferies Financial Group lifted their target price on PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Ten analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $81.33.

PTC Therapeutics Trading Up 1.4%

Shares of PTC Therapeutics stock opened at $69.90 on Friday. The stock’s fifty day moving average price is $75.01 and its 200-day moving average price is $67.78. The firm has a market cap of $5.61 billion, a P/E ratio of 8.17 and a beta of 0.48. PTC Therapeutics has a 12 month low of $35.95 and a 12 month high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). The business had revenue of $164.68 million during the quarter, compared to analysts’ expectations of $281.45 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm’s revenue was down 22.7% compared to the same quarter last year. During the same period last year, the company earned ($0.85) earnings per share. Analysts forecast that PTC Therapeutics will post -4.52 earnings per share for the current year.

Insider Buying and Selling

In other PTC Therapeutics news, CAO Christine Marie Utter sold 1,034 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $76.45, for a total value of $79,049.30. Following the completion of the sale, the chief accounting officer owned 72,693 shares of the company’s stock, valued at approximately $5,557,379.85. This trade represents a 1.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Pauwels sold 1,024 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $78.70, for a total transaction of $80,588.80. Following the transaction, the insider owned 80,141 shares in the company, valued at approximately $6,307,096.70. This trade represents a 1.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 276,765 shares of company stock valued at $21,903,948 in the last 90 days. 5.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC purchased a new stake in shares of PTC Therapeutics during the first quarter valued at $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in PTC Therapeutics by 11.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock worth $9,109,000 after acquiring an additional 18,504 shares during the period. Allspring Global Investments Holdings LLC lifted its position in PTC Therapeutics by 22.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 12,545 shares of the biopharmaceutical company’s stock worth $613,000 after acquiring an additional 2,258 shares during the period. AlphaQuest LLC grew its stake in PTC Therapeutics by 337.7% during the 2nd quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock valued at $386,000 after purchasing an additional 6,102 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D increased its holdings in shares of PTC Therapeutics by 7.0% in the second quarter. State of New Jersey Common Pension Fund D now owns 41,376 shares of the biopharmaceutical company’s stock valued at $2,021,000 after purchasing an additional 2,701 shares during the period.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full‑year 2025 product and royalty revenue came in at $831M, exceeding company guidance, showing underlying sales resilience. PR Newswire Release
• Positive Sentiment: Sephience (sepiapterin), launched in 2H‑2025, showed strong uptake with Q4 revenue of $92M and $111M for full year 2025—this product momentum is a key upside driver if growth continues. PR Newswire Release
• Positive Sentiment: PTC ended 2025 with approximately $1.95B in cash, which provides a sizable runway to fund launches, R&D and potential business development. PR Newswire Release
• Neutral Sentiment: Company filed Q4 results and held a conference call; investors should listen for management’s details on Sephience rollout pace, expense outlook and timing of pipeline catalysts. Q4 Press Release / Slides
• Negative Sentiment: Q4 EPS missed badly: loss of $1.67 vs. consensus loss near $0.37 (Zacks reports similar misses), and revenue of $164.7M fell well short of the ~$281M estimate—these misses are the primary driver of the stock decline. Zacks: Q4 Loss & Revenue Miss
• Negative Sentiment: FY‑2026 revenue guidance was set at $700–$800M versus consensus near $974M, signaling a significant step‑down in near‑term top‑line expectations and increasing downside risk to estimates. PR Newswire Release
• Negative Sentiment: Market media flagged further investor concern after the company’s Translarna NDA withdrawal raised questions about regulatory/pathway risk for that program. Yahoo Finance: Translarna NDA Withdrawal
• Negative Sentiment: Insider selling: VP Mark Boulding sold ~5,894 shares over Feb. 17–18 at ~\$69.3/share; while not uncommon, the disclosed sales add to near‑term negative sentiment. SEC Form 4

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.